Drug, alcohol and tobacco use disorders are a global burden affecting millions of people.
Despite decades of research, treatment options are sparse or missing, and relapse rates are …

Meal ingestion provokes the release of hormones and transmitters, which in turn regulate
energy homeostasis and feeding behavior. One such hormone, glucagon-like peptide-1 …

Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers
glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic …

Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …

The most successful obesity therapeutics, glucagon-like peptide-1 receptor (GLP1R)
agonists, cause aversive responses such as nausea and vomiting,, effects that may …

Tobacco smokers titrate their nicotine intake to avoid its noxious effects, sensitivity to which
may influence vulnerability to tobacco dependence, yet mechanisms of nicotine avoidance …

Although the multifaceted mechanisms underlying alcohol use disorder (AUD) have been
partially defined, the neurobiological complexity of this disorder is yet to be unraveled. One …

Dysfunctional signaling in midbrain reward circuits perpetuates diseases characterized by
compulsive overconsumption of rewarding substances such as substance abuse, binge …

The glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide is approved for the
treatment of obesity; however, there is still much to be learned regarding the neuronal sites …

Increasing the therapeutic potential and reducing the side effects of US Food and Drug
Administration–approved glucagon-like peptide-1 receptor (GLP-1R) agonists used to treat …